JONES FINANCIAL COMPANIES LLLP
Position in VTGN — Vistagen Therapeutics, Inc.
CIK 815917
DES PERES, MO
Position in VTGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$64
-$11 QoQ
Shares Held
114
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in VTGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026JONES FINANCIAL COMPANIES LLLP holds $238,312,048 across 270 Biotechnology names. VTGN ranks #255 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
202,860 | $90,585,104 | |
| 2 | TECH |
BIO-TECHNE Corp
|
624,063 | $32,613,531 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
73,643 | $24,366,258 | |
| 4 | ARGX |
Argenx SE
|
16,809 | $12,274,771 | |
| 5 | ARDX |
Ardelyx, Inc.
|
1,858,891 | $11,134,757 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
12,763 | $9,861,203 | |
| 7 | SLS |
SELLAS Life Sciences Group, Inc.
|
1,675,077 | $7,085,575 | |
| 8 | INSM |
INSMED Inc
|
41,406 | $6,770,708 |
All Filings in VTGN
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $64 | 114 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $75 | 114 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $404 | 114 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $228 | 114 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $200 | 80 | Shares | Sole | 2025-05-28 | |
| 2024-12-31 | $826 | 280 | Shares | Sole | 2025-02-06 | |
| 2024-09-30 | $240 | 80 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $278 | 80 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $422 | 80 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $411 | 80 | Shares | Sole | 2024-02-13 | |
| No filing history on record for this holder in this stock. | ||||||